Mathew E. Sowa

Mathew E. Sowa

Auto-generated profile, based on publicly available information

Mathew E. Sowa

C4 Therapeutics, Inc., Watertown, Massachusetts

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
USUddhav K. Shigdel
Uddhav K. Shigdel
SLSeung-Joo Lee
Seung-Joo Lee
MSMathew E. Sowa
Mathew E. Sowa
BBBrian R. Bowman
Brian R. Bowman
KRKeith Robison
Keith Robison
GVGregory L. Verdine
Gregory L. Verdine
Significance: This manuscript reports on a member of the FK506/rapamycin family, WDB002, and the realization that FKBP-mediated recognition is a genetically programmable modality that enables engagement of topologically flat targets. FKBP-mediated recognition is thus nature’s strategy for drugging the “undruggable.” The surface of FKBP engages three completely unrelated targets—calcineurin, MTOR, and CEP250—with high-target affinity and specificity, using different constellations of amino acid residues. Target specificity is determined solely by the “variable domain” of the bound small molecule alone, suggesting the modality might be generalizable to other undruggable targets through variable domain engineering. Finally, since WDB002 targets CEP250, it may be a promising starting point for developing a treatment for COVID-19.

28 October 2025 in Cancer Research
Verified
Journal Article
Closed access
BKBridget T. Kreger
Bridget T. Kreger
YLYanke Liang
Yanke Liang
NRNicole M. Reilly
Nicole M. Reilly
MSMeghan E. Spears
Meghan E. Spears
WSWilliam A. Scott
William A. Scott
MSMathew E. Sowa
Mathew E. Sowa
Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer–driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by developing CFT1946, a potent, orally bioavailable, and brain-penetrant cereblon-based bifunctional degrader that targets BRAFV600-mutant protein while sparing wild-type RAF family members. CFT1946 demonstrated potent activity in preclinical models of BRAFV600-mutant driven melanoma and colorectal cancer while sparing wild-type MAPK signaling and mitigating the paradoxical activation associated with approved BRAFis. CFT1946 was efficacious in an intracranial BRAFV600E melanoma tumor model and demonstrated robust activity in multiple cellular and patient-derived BRAFV600-mutant melanoma and colorectal cancer models of acquired and adaptive RAF dimer–driven BRAFi resistance. CFT1946 therefore represents an effective therapeutic modality with the potential to overcome the key limitations of current BRAFV600-mutant targeted therapies. Significance: CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer–driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289